邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

涎液化糖链抗原-6在间质性肺疾病诊疗中的价值

周惠琼,  张奉春

downloadPDF
文章导航 > 协和医学杂志  > 2018 >  9(3): 207-212
周惠琼, 张奉春. 涎液化糖链抗原-6在间质性肺疾病诊疗中的价值[J]. 协和医学杂志, 2018, 9(3): 207-212. doi: 10.3969/j.issn.1674-9081.2018.03.004
引用本文: 周惠琼, 张奉春. 涎液化糖链抗原-6在间质性肺疾病诊疗中的价值[J]. 协和医学杂志, 2018, 9(3): 207-212. doi: 10.3969/j.issn.1674-9081.2018.03.004
shu
Hui-qiong ZHOU, Feng-chun ZHANG. The Value of Krebs von den Lungen-6 in the Clinical Management of Interstitial Lung Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 207-212. doi: 10.3969/j.issn.1674-9081.2018.03.004
Citation: Hui-qiong ZHOU, Feng-chun ZHANG. The Value of Krebs von den Lungen-6 in the Clinical Management of Interstitial Lung Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 207-212. doi: 10.3969/j.issn.1674-9081.2018.03.004
shu

涎液化糖链抗原-6在间质性肺疾病诊疗中的价值

doi: 10.3969/j.issn.1674-9081.2018.03.004
  • 1.

    解放军总医院第一附属医院风湿科, 北京 100048

  • 2.

    中国医学科学院 北京协和医学院 北京协和医院 风湿免疫科, 北京 100730

  • 3.

    中国医学科学院 北京协和医学院 北京协和医院 教育部重点实验室, 北京 100730

详细信息
    通讯作者:

    张奉春 电话:010-69155007, E-mail:zhangfccra@aliyun.com

  • 中图分类号: R563.1

The Value of Krebs von den Lungen-6 in the Clinical Management of Interstitial Lung Diseases

  • 1.

    Department of Rheumatology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China

  • 2.

    Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    The Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 间质性肺疾病(interstitial lung disease, ILD)是以弥漫性肺实质、肺泡炎症和间质纤维化为基本病理表现的慢性进展型疾病, 缺乏特异性诊断方法。血清学标志物, 特别是涎液化糖链抗原-6(Krebs von den Lungen-6, KL-6), 正日益受到人们关注。KL-6是一种跨膜高分子量黏蛋白, 主要表达于Ⅱ型肺泡细胞和支气管上皮细胞的细胞质和胞膜。近年来, 大量研究发现KL-6表达可能与肿瘤、部分新生儿肺部疾病、ILD及其恶化、急性肺损伤等疾病相关, 其在ILD中的作用受到特别关注, 但具体机制仍不清楚。本文对KL-6的结构特点, 其在ILD患者血清及肺泡灌洗液中的异常表现与ILD病变发生、进展、药物疗效及预后的相关性作一综述, 以期为临床研究提供最新信息。
    Abstract: Interstitial lung diseases (ILDs) are a group of diverse pulmonary disorders characterized by various patterns of inflammation and fibrosis in the interstitium of the lung. There are no specific diagnostic methods for ILDs currently and various serum biomarkers, including Krebs von den Lungen-6 (KL-6), have been tested for their use in diagnosing ILDs. However, the pathophysiological role of KL-6 in patients with ILDs is not yet very clear. KL-6 is high-molecular-weight glycoprotein and moderately expressed in type Ⅱ pneumocytes and respiratory bronchiolar epithelial cells. KL-6 has been found to have an association with various types of diseases such as cancers, some neonatal lung diseases, ILDs, and acute lung injury. In this article, we review the structure of KL-6 and the relationship between the elevation of KL-6 and the etiology, progression, treatment evaluation, and prognosis of ILDs.
    • HTML全文
    • 参考文献(36)
  • [1] Tzouvelekis A, Kouliatsis G, Anevlavis S, et al. Serum biomarkers in interstitial lung diseases[J]. Respir Res, 2005, 6:1-24. doi:  10.1186/1465-9921-6-1
    [2] Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50:3-13. doi:  10.1016/j.resinv.2012.02.001
    [3] Kohno N, Akiyama M, Kyoizumi S, et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma[J]. Jpn J Clin Oncol, 1988, 18:203-216. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=HighWire000005639932
    [4] Stahel RA, Gilks WR, Lehmann HP, et al.Third International Work shop on Lung Tumor and Differentiation Anti-gens:overview of the results of the central data analysis[J].Int J Cancer(Suppl), 1994, 8:6-26. http://www.onacademic.com/detail/journal_1000033846762610_85d3.html
    [5] Ohtsuki Y, Fujita J, Hachisuka Y, et al, Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen(EMA)in presumably normal pulmonary tissue and in interstitial pneumonia[J].Med Mol Morphol, 2007, 40:198-202. doi:  10.1007/s00795-007-0382-7
    [6] Hattrup CL, Gendier SJ.Structure and function of the cell surface (tethered) mucins[J].Annu Rev Physiol, 2008, 70:431-457. doi:  10.1146/annurev.physiol.70.113006.100659
    [7] DoiM, Yokoyama A, Kondo K, et al.Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUCl capping[J].Cancer Sci, 2006, 97:420-429. doi:  10.1111/j.1349-7006.2006.00183.x
    [8] Hirasawa Y, Kohno N, Yokoyama A, et al.KL-6, a human MUCl mucin, is chemotactic for human fibroblasts[J].Am J Respir Cell Mol Biol, 1997, 17:501-507. doi:  10.1165/ajrcmb.17.4.2253
    [9] Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6[J]. Chest, 1989, 96:68-73. doi:  10.1378/chest.96.1.68
    [10] Xu L, Yan DR, Zhu SL, et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation[J]. Eur Rev Med Pharmacol Sci, 2013, 17:3073-3077. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=7c341d370b53f86b9f25fcff65fe997e
    [11] Ohshimo S, Yokoyama A, Hattori N, et al.KL-6, a human MUC1/mucin, promotes proliferation and survival of lung fibroblasts[J].Bio chem Biophys Res Commun, 2005, 338:1845-1852. doi:  10.1016/j.bbrc.2005.10.144
    [12] Xu L, Yang D, Zhu S, et al. Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6[J]. Experimental Lung Research, 2013, 39, 241-248. doi:  10.3109/01902148.2013.798056
    [13] Shimizu Y, Kuwabara H, Ono A, et al. Intracellular Th1/Th2 balance of pulmonary CD4(+) T cells in patients with active interstitial pneumonia evaluated by serum KL-6[J]. Immunopharmacol Immunotoxicol, 2006, 28:295-304. doi:  10.1080/08923970600809389
    [14] Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50:3-13. doi:  10.1016/j.resinv.2012.02.001
    [15] Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases[J]. Am J Respir Crit Care Med, 2002, 165:378-381. doi:  10.1164/ajrccm.165.3.2107134
    [16] 朱晨, 赵亚滨, 孔灵菲, 等.涎液化糖链抗原-6在不同类型的弥漫性间质性肺疾病患者血清和支气管肺泡灌洗液中的表达及临床意义[J].中华结核和呼吸杂志, 2016, 39:93-97. doi:  10.3760/cma.j.issn.1001-0939.2016.02.004
    [17] Sugaya A, Ishiguro S, Mitsuhashi S, et al. Interstitial lung disease associated with trastuzumab monotherapy:A report of 3 cases[J]. Mol Clin Oncol, 2017, 6:229-232. doi:  10.3892/mco.2016.1113
    [18] Miyata M, Sakuma F, Fukaya E, et al. Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis[J]. Intern Med, 2002, 41:467-473. doi:  10.2169/internalmedicine.41.467
    [19] 赵亚东, 李振华, 康健, 等.特发性肺纤维化患者血清及支气管肺泡灌洗液中KL-6水平及其意义[J].中华内科杂志, 2007, 46:151-152. doi:  10.3760/j.issn:0578-1426.2007.02.023
    [20] Hamai K, Iwamoto H, Ishikawa N, et al.Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis[J]. Dis Markers, 2016, 17:4759040-4759048. http://www.ncbi.nlm.nih.gov/pubmed/27293304
    [21] Sokai A, Tanizawa K, Handa T, et al.Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis[J]. ERJ Open Res, 2017, 3:30. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576222/
    [22] Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis[J]. Respirology, 2006, 11:164-168. doi:  10.1111/j.1440-1843.2006.00834.x
    [23] Ohshimo S, Ishikawa N, Horimasu Y, et al.Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis[J].Respir Med, 2014, 108:1031-1039. doi:  10.1016/j.rmed.2014.04.009
    [24] Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis:A systematic review and meta-analysis[J]. Clin Respir J, 2018, 12:1084-1092. doi:  10.1111/crj.12631
    [25] Oguz EO, Kucuksahin O, Turgay M, et al. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease:a cross-sectional study[J]. Clin Rheumatol, 2016, 35:663-666. doi:  10.1007/s10067-015-3167-8
    [26] Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases[J]. J Rheumatol, 2000, 27:1164-1170. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=689f1a6522655569b0cfaadf4a8180ad
    [27] 王冉冉, 田美伊, 杨金水, 等.血清KL-6水平对评价结缔组织病间质性肺疾病作用的研究[J].中国临床医生杂志, 2017, 45:36-40. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zglcys201703012
    [28] Benyamine A, Heim X, Resseguier N, et al. Elevated serum Krebs von den Lungen-6 in systemic sclerosis:a marker of lung fibrosis and severity of the disease[J]. Rheumatol Int, 2018, 38:813-819. doi:  10.1007/s00296-018-3987-3
    [29] Kumánovics G, Gorbe E, Minier T, et al. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis[J]. Clin Exp Rheumatol, 2014, 32:S138-S144. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=4a461e9c7c187a78bd6af3f8de34f52e
    [30] Kuwana M, Shirai Y, Takeuchi T. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease[J]. J Rheumatol, 2016, 43:1825-1831. doi:  10.3899/jrheum.160339
    [31] Sugiyama Y, Yoshimi R, Tamura M, et al. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease[J]. Arthritis Res Ther, 2018, 20:7. doi:  10.1186/s13075-017-1506-7
    [32] 卢昕, 谢瑶, 王国春.血清KL-6检测在特发性炎性肌病伴肺间质病变诊断中的价值[J].中华风湿病学杂志, 2006, 10:416-419. doi:  10.3760/j:issn:1007-7480.2006.07.009
    [33] Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis[J]. Ann Rheum Dis, 2000, 59:257-262. doi:  10.1136/ard.59.4.257
    [34] Chen F, Lu X, Shu X. et al. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis:a comparative and prospective study[J]. Intern Med J, 2015, 6:8. http://www.ncbi.nlm.nih.gov/pubmed/25827843
    [35] Iwata Y, Wada T, Furuichi K, et al. Serum levels of KL-6 reflect disease activity of interstitial pneumonia associated with ANCA related vasculitis[J]. Intern Med, 2001, 40:1093-1097. doi:  10.2169/internalmedicine.40.1093
    [36] Lee YS, Kim HC, Lee BY, et al.The value of biomarkers as predictors of outcome in patients with rheumatoid arthritis-associated usual interstitial pneumonia[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2016, 33:216-223. http://www.ncbi.nlm.nih.gov/pubmed/27758986
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  147
  • HTML全文浏览量:  9
  • PDF下载量:  153
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-04-03
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计